Maprotiline

Generic name: Pronounced as (ma proe' ti leen)
Brand names
  • Ludiomil®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 05/15/2017

A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as maprotiline during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant. Children younger than 18 years of age should not normally take maprotiline, but in some cases, a doctor may decide that maprotiline is the best medication to treat a child's condition.

You should know that your mental health may change in unexpected ways when you take maprotiline or other antidepressants even if you are an adult over 24 years of age. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; and frenzied abnormal excitement. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Your healthcare provider will want to see you often while you are taking maprotiline, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.

The doctor or pharmacist will give you the manufacturer's patient information sheet (medication guide) when you begin treatment with maprotiline. Read the information carefully and ask your doctor or pharmacist if you have any questions. You also can obtain the Medication Guide from the FDA website: http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm.

No matter what your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.

Maprotiline is used to treat depression, bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods), and anxiety. Maprotiline is in a class of medications called tetracyclic antidepressants. It works by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance.

Maprotiline comes as a tablet to take by mouth. It is usually taken one to three times a day and may be taken with or without food. Take maprotiline at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take maprotiline exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

It may take a few weeks or longer for you to feel the full benefit of maprotiline. Continue to take maprotiline even if you feel well. Do not stop taking maprotiline without talking to your doctor. Your doctor will probably want to decrease your dose gradually.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Before taking maprotiline,

  • tell your doctor and pharmacist if you are allergic to maprotiline or any other medications.

  • tell your doctor if you are taking a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate), or if you have taken an MAO inhibitor during the past 14 days. Your doctor will probably tell you that you should not take maprotiline.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (blood thinners) such as warfarin (Coumadin); antihistamines; estrogens; fluoxetine (Prozac); levodopa (Sinemet, Larodopa); lithium (Eskalith, Lithobid); medication for high blood pressure, seizures, Parkinson's disease, asthma, colds, or allergies; methylphenidate (Ritalin); muscle relaxants; oral contraceptives; sedatives; sleeping pills; thyroid medication; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had glaucoma (an eye condition), an enlarged prostate (a male reproductive gland), difficulty urinating, seizures, a brain tumor, a head injury, an overactive thyroid gland, or liver, kidney, or heart disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking maprotiline, call your doctor.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking maprotiline.

  • you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • remember that alcohol can add to the drowsiness caused by this medication.

  • tell your doctor if you use tobacco products. Cigarette smoking may decrease the effectiveness of this medication.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Maprotiline may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • drowsiness

    • weakness or tiredness

    • nightmares

    • dry mouth

    • skin more sensitive to sunlight than usual

    • changes in appetite or weight

    • constipation

    • difficulty urinating

    • frequent urination

    • blurred vision

    • changes in sex drive or ability

    • excessive sweating

  • Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:

    • jaw, neck, and back muscle spasms

    • slow or difficult speech

    • shuffling walk

    • uncontrollable shaking of a part of the body

    • fever, chills, sore throat, or flu-like symptoms

    • difficulty breathing or swallowing

    • rash

    • yellowing of the skin or eyes

    • irregular heartbeat

  • Maprotiline may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to maprotiline.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The metabolism of Maprotiline can be decreased when combined with Moxifloxacin.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The metabolism of Maprotiline can be increased when combined with Insulin glargine.
Leflunomide Leflunomide The serum concentration of Maprotiline can be decreased when it is combined with Leflunomide.
Delavirdine Delavirdine The metabolism of Maprotiline can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Maprotiline can be decreased when combined with Nevirapine.
Dolasetron Dolasetron The risk or severity of adverse effects can be increased when Dolasetron is combined with Maprotiline.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Maprotiline.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Maprotiline.
Cilostazol Cilostazol The metabolism of Cilostazol can be decreased when combined with Maprotiline.
Clopidogrel Clopidogrel The metabolism of Maprotiline can be decreased when combined with Clopidogrel.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Maprotiline is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The metabolism of Maprotiline can be decreased when combined with Conjugated estrogens.
Fenofibrate Fenofibrate Maprotiline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Guanfacine Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Magnesium Hydroxide Magnesium Hydroxide Maprotiline may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium Oxide Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Maprotiline.
Mycophenolate Mycophenolate Maprotiline may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Maprotiline is combined with Naratriptan.
Olsalazine Olsalazine Olsalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Maprotiline.
Potassium Potassium Potassium may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone Prednisone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Maprotiline.
Ranitidine Ranitidine The metabolism of Maprotiline can be decreased when combined with Ranitidine.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Maprotiline.
Rizatriptan Rizatriptan Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.
Sumatriptan Sumatriptan Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Tacrolimus Tacrolimus Tacrolimus may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tizanidine Tizanidine Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Zolmitriptan Zolmitriptan The metabolism of Maprotiline can be decreased when combined with Zolmitriptan.
Ampicillin Injection Ampicillin Injection Ampicillin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Maprotiline.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Maprotiline.
Foscarnet Injection Foscarnet Injection Foscarnet may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.
Interferon Beta-1b Injection Interferon Beta-1b Injection The metabolism of Maprotiline can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The metabolism of Maprotiline can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Levofloxacin.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Meperidine.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Maprotiline is combined with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Maprotiline.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Maprotiline may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine Amphetamine may decrease the sedative and stimulatory activities of Maprotiline.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cyclosporine Cyclosporine The metabolism of Maprotiline can be decreased when combined with Cyclosporine.
Ondansetron Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Maprotiline.
Granisetron Granisetron The risk or severity of adverse effects can be increased when Granisetron is combined with Maprotiline.
Torsemide Torsemide Torasemide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Olanzapine Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Maprotiline.
Alosetron Alosetron The metabolism of Maprotiline can be decreased when combined with Alosetron.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dofetilide.
Entacapone Entacapone Entacapone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Hydroxychloroquine Hydroxychloroquine The metabolism of Maprotiline can be decreased when combined with Hydroxychloroquine.
Meloxicam Meloxicam Meloxicam may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxcarbazepine Oxcarbazepine Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pantoprazole Pantoprazole Pantoprazole may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Temozolomide Temozolomide Temozolomide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Zaleplon Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Anakinra Anakinra The metabolism of Maprotiline can be increased when combined with Anakinra.
Desloratadine Desloratadine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Maprotiline.
Rivastigmine Rivastigmine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine The metabolism of Maprotiline can be decreased when combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Maprotiline can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Maprotiline is combined with Glycopyrronium.
Modafinil Modafinil The metabolism of Maprotiline can be increased when combined with Modafinil.
Perindopril Perindopril Perindopril may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Epinephrine Injection Epinephrine Injection The risk or severity of Tachycardia can be increased when Epinephrine is combined with Maprotiline.
Eplerenone Eplerenone Eplerenone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of serotonin syndrome can be increased when Maprotiline is combined with Escitalopram.
Zonisamide Zonisamide Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Adalimumab Injection Adalimumab Injection The metabolism of Maprotiline can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of adverse effects can be increased when Maprotiline is combined with Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Maprotiline.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Maprotiline is combined with Dexmethylphenidate.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Almotriptan Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Maprotiline.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Maprotiline.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Maprotiline.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Maprotiline.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Maprotiline.
Emtricitabine Emtricitabine Emtricitabine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection Interferon Beta-1a Subcutaneous Injection The metabolism of Maprotiline can be decreased when combined with Interferon beta-1a.
Memantine Memantine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Memantine.
Tegaserod Tegaserod The metabolism of Maprotiline can be decreased when combined with Tegaserod.
Tadalafil Tadalafil Tadalafil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Frovatriptan Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Maprotiline.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Maprotiline can be decreased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Maprotiline.
Infliximab Injection Infliximab Injection The metabolism of Maprotiline can be increased when combined with Infliximab.
Protriptyline Protriptyline Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Duloxetine Duloxetine The metabolism of Maprotiline can be decreased when combined with Duloxetine.
Tinidazole Tinidazole Tinidazole may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Trospium Trospium Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Cefditoren Cefditoren Cefdinir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cinacalcet Cinacalcet The metabolism of Maprotiline can be decreased when combined with Cinacalcet.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Maprotiline.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Maprotiline is combined with Eszopiclone.
Ganciclovir Ganciclovir Maprotiline may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Ribavirin Ribavirin Ribavirin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Solifenacin Solifenacin Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Valganciclovir Valganciclovir Maprotiline may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Maprotiline.
Adefovir Adefovir Adefovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine Amphetamine may decrease the sedative and stimulatory activities of Maprotiline.
Entecavir Entecavir The metabolism of Maprotiline can be decreased when combined with Entecavir.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The metabolism of Maprotiline can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Maprotiline can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Maprotiline.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Maprotiline.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Maprotiline is combined with Isocarboxazid.
Ramelteon Ramelteon Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Darifenacin Darifenacin The metabolism of Maprotiline can be decreased when combined with Darifenacin.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Maprotiline is combined with Fentanyl.
Pregabalin Pregabalin The therapeutic efficacy of Maprotiline can be increased when used in combination with Pregabalin.
Deferasirox Deferasirox The serum concentration of Maprotiline can be increased when it is combined with Deferasirox.
Phenylephrine Phenylephrine The metabolism of Maprotiline can be increased when combined with Phenylephrine.
Tipranavir Tipranavir The metabolism of Maprotiline can be decreased when combined with Tipranavir.
Felbamate Felbamate Felbamate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ranolazine Ranolazine The serum concentration of Maprotiline can be increased when it is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Maprotiline can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Maprotiline.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Imatinib.
Sitagliptin Sitagliptin Maprotiline may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Varenicline Varenicline Maprotiline may decrease the excretion rate of Varenicline which could result in a higher serum level.
Gefitinib Gefitinib The metabolism of Maprotiline can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Salbutamol.
Paliperidone Paliperidone The risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone.
Bortezomib Bortezomib The metabolism of Maprotiline can be decreased when combined with Bortezomib.
Clofarabine Injection Clofarabine Injection Clofarabine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The metabolism of Maprotiline can be increased when combined with Insulin glulisine.
Lubiprostone Lubiprostone Maprotiline may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Posaconazole.
Primaquine Primaquine The metabolism of Primaquine can be decreased when combined with Maprotiline.
Pemetrexed Injection Pemetrexed Injection Maprotiline may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lisdexamfetamine Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Maprotiline.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Vorinostat.
Sorafenib Sorafenib The metabolism of Maprotiline can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Sunitinib.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Lapatinib.
Levocetirizine Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pegaptanib Injection Pegaptanib Injection Maprotiline may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Maprotiline.
Mexiletine Mexiletine The metabolism of Maprotiline can be decreased when combined with Mexiletine.
Armodafinil Armodafinil The metabolism of Maprotiline can be increased when combined with Armodafinil.
Azacitidine Injection Azacitidine Injection Azacitidine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Maprotiline.
Temsirolimus Temsirolimus The metabolism of Maprotiline can be decreased when combined with Temsirolimus.
Lenalidomide Lenalidomide Lenalidomide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nilotinib Nilotinib The metabolism of Nilotinib can be decreased when combined with Maprotiline.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Toremifene.
Budesonide Budesonide Maprotiline may decrease the excretion rate of Budesonide which could result in a higher serum level.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Betaine Betaine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum Toxin Type B.
Doripenem Injection Doripenem Injection Maprotiline may decrease the excretion rate of Doripenem which could result in a higher serum level.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.
Cevimeline Cevimeline Cevimeline may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nebivolol Nebivolol The metabolism of Nebivolol can be decreased when combined with Maprotiline.
Bendamustine Injection Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Maprotiline.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Maprotiline.
Certolizumab Injection Certolizumab Injection The metabolism of Maprotiline can be increased when combined with Certolizumab pegol.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Maprotiline.
Methylnaltrexone Injection Methylnaltrexone Injection Maprotiline may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline.
Midazolam Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Maprotiline.
Naltrexone Injection Naltrexone Injection The risk or severity of adverse effects can be increased when Naltrexone is combined with Maprotiline.
Dexrazoxane Injection Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Eltrombopag Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Maprotiline.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Maprotiline is combined with Milnacipran.
Plerixafor Injection Plerixafor Injection Maprotiline may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Maprotiline.
Fesoterodine Fesoterodine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Degarelix.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Betaxolol.
Iloperidone Iloperidone The risk or severity of adverse effects can be increased when Maprotiline is combined with Iloperidone.
Prasugrel Prasugrel Maprotiline may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide Lacosamide Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Everolimus Everolimus The metabolism of Maprotiline can be decreased when combined with Everolimus.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone Dronedarone The metabolism of Dronedarone can be decreased when combined with Maprotiline.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.
Pralatrexate Injection Pralatrexate Injection Maprotiline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Saxagliptin Saxagliptin Maprotiline may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Topotecan Topotecan Maprotiline may decrease the excretion rate of Topotecan which could result in a higher serum level.
Golimumab Injection Golimumab Injection The metabolism of Maprotiline can be increased when combined with Golimumab.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Pazopanib.
Asenapine Asenapine The risk or severity of adverse effects can be increased when Maprotiline is combined with Asenapine.
Vigabatrin Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Albendazole Albendazole The metabolism of Maprotiline can be decreased when combined with Albendazole.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Maprotiline is combined with Oxymorphone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Maprotiline can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine The risk or severity of seizure can be increased when Maprotiline is combined with Dalfampridine.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Eribulin.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Maprotiline is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection The metabolism of Maprotiline can be decreased when combined with Acetaminophen.
Vilazodone Vilazodone The metabolism of Vilazodone can be decreased when combined with Maprotiline.
Ipilimumab Injection Ipilimumab Injection Maprotiline may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Maprotiline.
Roflumilast Roflumilast Maprotiline may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Rilpivirine Rilpivirine The metabolism of Maprotiline can be decreased when combined with Rilpivirine.
Abiraterone Abiraterone The serum concentration of Maprotiline can be increased when it is combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Triptorelin.
Rivaroxaban Rivaroxaban Maprotiline may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Ruxolitinib Ruxolitinib Maprotiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Vandetanib.
Clobazam Clobazam The metabolism of Maprotiline can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The serum concentration of Maprotiline can be increased when it is combined with Vemurafenib.
Deferiprone Deferiprone Maprotiline may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Maprotiline.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Crizotinib.
Cabergoline Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Maprotiline.
Naloxone Injection Naloxone Injection Maprotiline may decrease the excretion rate of Naloxone which could result in a higher serum level.
Fondaparinux Injection Fondaparinux Injection Fondaparinux may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ezogabine Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Enzalutamide Enzalutamide Maprotiline may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Mirabegron Mirabegron The risk or severity of urinary retention can be increased when Maprotiline is combined with Mirabegron.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Maprotiline.
Teriflunomide Teriflunomide The serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.
Teduglutide Injection Teduglutide Injection Maprotiline may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Bedaquiline.
Alogliptin Alogliptin Maprotiline may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Maprotiline.
Pomalidomide Pomalidomide Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Canagliflozin Canagliflozin Maprotiline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Maprotiline can be decreased when combined with Ospemifene.
Trametinib Trametinib Maprotiline may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.
Ertapenem Injection Ertapenem Injection Ertapenem may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Vortioxetine Vortioxetine The risk or severity of adverse effects can be increased when Maprotiline is combined with Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Maprotiline.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Simeprevir Simeprevir The metabolism of Maprotiline can be decreased when combined with Simeprevir.
Sofosbuvir Sofosbuvir Maprotiline may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin Dapagliflozin The metabolism of Maprotiline can be decreased when combined with Dapagliflozin.
Apremilast Apremilast The metabolism of Maprotiline can be increased when combined with Apremilast.
Droxidopa Droxidopa Maprotiline may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Maprotiline can be increased when combined with Siltuximab.
Eslicarbazepine Eslicarbazepine Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Belinostat Injection Belinostat Injection The metabolism of Maprotiline can be increased when combined with Belinostat.
Testosterone Injection Testosterone Injection Testosterone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oritavancin Injection Oritavancin Injection The metabolism of Maprotiline can be decreased when combined with Oritavancin.
Hydrocodone Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Suvorexant Suvorexant Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Edoxaban Edoxaban Maprotiline may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The metabolism of Maprotiline can be decreased when combined with Peginterferon beta-1a.
Methamphetamine Methamphetamine Metamfetamine may decrease the sedative and stimulatory activities of Maprotiline.
Tasimelteon Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pirfenidone Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Maprotiline.
Secukinumab Injection Secukinumab Injection The metabolism of Maprotiline can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Maprotiline.
Insulin Human Inhalation Insulin Human Inhalation The metabolism of Maprotiline can be increased when combined with Insulin human.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Lenvatinib.
Naloxegol Naloxegol The metabolism of Maprotiline can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Maprotiline can be decreased when combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Maprotiline.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ivabradine.
Amiloride Amiloride Amiloride may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Macitentan Macitentan Maprotiline may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.
Rolapitant Rolapitant The metabolism of Maprotiline can be decreased when combined with Rolapitant.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Maprotiline is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Maprotiline.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Maprotiline is combined with Cariprazine.
Penicillin G Procaine Injection Penicillin G Procaine Injection Maprotiline may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Maprotiline is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The metabolism of Maprotiline can be increased when combined with Insulin degludec.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Maprotiline.
Osimertinib Osimertinib The serum concentration of Maprotiline can be decreased when it is combined with Osimertinib.
Ixazomib Ixazomib Maprotiline may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad Lesinurad Maprotiline may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Brivaracetam Injection Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Cobicistat Cobicistat The metabolism of Maprotiline can be decreased when combined with Cobicistat.
Midodrine Midodrine The risk or severity of Tachycardia can be increased when Midodrine is combined with Maprotiline.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Maprotiline is combined with Pimavanserin.
Obeticholic Acid Obeticholic Acid The metabolism of Maprotiline can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Diphenhydramine.
Furosemide Injection Furosemide Injection Furosemide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib Rucaparib The metabolism of Rucaparib can be decreased when combined with Maprotiline.
Lixisenatide Injection Lixisenatide Injection Maprotiline may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Maprotiline.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Deutetrabenazine.
Valbenazine Valbenazine Maprotiline may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Safinamide Safinamide The risk or severity of adverse effects can be increased when Safinamide is combined with Maprotiline.
Naldemedine Naldemedine Maprotiline may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin Midostaurin The metabolism of Maprotiline can be decreased when combined with Midostaurin.
Enasidenib Enasidenib The metabolism of Maprotiline can be decreased when combined with Enasidenib.
Benznidazole Benznidazole Maprotiline may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Delafloxacin.
Letermovir Letermovir The metabolism of Letermovir can be decreased when combined with Maprotiline.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin Ertugliflozin may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Buprenorphine Injection Buprenorphine Injection Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide Maprotiline may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Baricitinib Baricitinib Maprotiline may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Lofexidine Lofexidine The therapeutic efficacy of Maprotiline can be increased when used in combination with Lofexidine.
Plazomicin Injection Plazomicin Injection Maprotiline may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Encorafenib.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Maprotiline.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ivosidenib.
Elagolix Elagolix The metabolism of Elagolix can be decreased when combined with Maprotiline.
Tafenoquine Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Maprotiline.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Maprotiline.
Dacomitinib Dacomitinib The metabolism of Maprotiline can be decreased when combined with Dacomitinib.
Stiripentol Stiripentol The metabolism of Maprotiline can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The therapeutic efficacy of Maprotiline can be decreased when used in combination with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Glasdegib.
Rifamycin Rifamycin The metabolism of Maprotiline can be decreased when combined with Rifamycin.
Prucalopride Prucalopride Maprotiline may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Maprotiline.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Maprotiline can be increased when combined with Emapalumab.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Brexanolone Injection Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Solriamfetol Solriamfetol The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Maprotiline.
Triclabendazole Triclabendazole The metabolism of Maprotiline can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Entrectinib.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Maprotiline.
Pitolisant Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Maprotiline.
Fedratinib Fedratinib The metabolism of Maprotiline can be decreased when combined with Fedratinib.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Maprotiline.
Phenytoin Injection Phenytoin Injection Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Fosphenytoin Injection Fosphenytoin Injection Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lumateperone Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Maprotiline is combined with Lasmiditan.
Cenobamate Cenobamate The therapeutic efficacy of Cenobamate can be decreased when used in combination with Maprotiline.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Maprotiline.
Capmatinib Capmatinib The metabolism of Maprotiline can be decreased when combined with Capmatinib.
Lemborexant Lemborexant Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Daratumumab and Hyaluronidase-fihj Injection Daratumumab and Hyaluronidase-fihj Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Maprotiline.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Fostemsavir.
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Maprotiline.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Maprotiline can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Relugolix.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Maprotiline is combined with Viloxazine.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Maprotiline.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Maprotiline.
Isotretinoin Isotretinoin Maprotiline may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate Sucralfate Sucralfate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Hydroxyurea Hydroxyurea The metabolism of Maprotiline can be decreased when combined with Hydroxyurea.
Floxuridine Floxuridine Floxuridine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Phenobarbital Phenobarbital Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Metaxalone Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Maprotiline.
Primidone Primidone The metabolism of Maprotiline can be increased when combined with Primidone.
Methsuximide Methsuximide Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Diethylpropion Diethylpropion Diethylpropion may decrease the sedative and stimulatory activities of Maprotiline.
Chlorpromazine Chlorpromazine The metabolism of Maprotiline can be decreased when combined with Chlorpromazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Maprotiline.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Maprotiline.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Maprotiline.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Maprotiline.
Carmustine Carmustine The metabolism of Maprotiline can be decreased when combined with Carmustine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Maprotiline.
Codeine Codeine The risk or severity of adverse effects can be increased when Maprotiline is combined with Codeine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Maprotiline.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.
Metaproterenol Metaproterenol The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Maprotiline.
Tranylcypromine Tranylcypromine The metabolism of Maprotiline can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Maprotiline.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Maprotiline.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.
Tetracycline Tetracycline Tetracycline may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Prochlorperazine Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Maprotiline.
Thioridazine Thioridazine The metabolism of Maprotiline can be decreased when combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Maprotiline.
Bleomycin Bleomycin Bleomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Sulfadiazine Sulfadiazine Sulfadiazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Maprotiline.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline.
Oxybutynin Oxybutynin Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Maprotiline.
Azathioprine Azathioprine The metabolism of Azathioprine can be decreased when combined with Maprotiline.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Maprotiline.
Phentermine Phentermine Phentermine may decrease the sedative and stimulatory activities of Maprotiline.
Methylphenidate Methylphenidate Methylphenidate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Amoxapine Amoxapine The metabolism of Maprotiline can be decreased when combined with Amoxapine.
Sulfasalazine Sulfasalazine Sulfasalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Doxorubicin Doxorubicin The metabolism of Maprotiline can be decreased when combined with Doxorubicin.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Mechlorethamine.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Pyridostigmine.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Carbamazepine Carbamazepine The metabolism of Maprotiline can be increased when combined with Carbamazepine.
Molindone Molindone The risk or severity of adverse effects can be increased when Maprotiline is combined with Molindone.
Methyldopa Methyldopa Maprotiline may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Maprotiline.
Hydralazine Hydralazine Maprotiline may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine Cimetidine The metabolism of Maprotiline can be decreased when combined with Cimetidine.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Warfarin Warfarin Maprotiline may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Loperamide.
Promethazine Promethazine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Griseofulvin Griseofulvin The metabolism of Maprotiline can be increased when combined with Griseofulvin.
Digoxin Digoxin Maprotiline may decrease the excretion rate of Digoxin which could result in a higher serum level.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Maprotiline.
Chloroquine Chloroquine The metabolism of Maprotiline can be decreased when combined with Chloroquine.
Quinine Quinine The metabolism of Quinine can be decreased when combined with Maprotiline.
Ethosuximide Ethosuximide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Triamterene Triamterene The metabolism of Maprotiline can be decreased when combined with Triamterene.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Maprotiline.
Chlorothiazide Chlorothiazide Maprotiline may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone Chlorthalidone Maprotiline may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone Metolazone Metolazone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital Secobarbital Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Desipramine Desipramine The metabolism of Desipramine can be decreased when combined with Maprotiline.
Amitriptyline Amitriptyline The metabolism of Maprotiline can be decreased when combined with Amitriptyline.
Imipramine Imipramine The metabolism of Maprotiline can be decreased when combined with Imipramine.
Probenecid Probenecid Maprotiline may decrease the excretion rate of Probenecid which could result in a higher serum level.
Quinidine Quinidine The metabolism of Quinidine can be decreased when combined with Maprotiline.
Procainamide Procainamide The metabolism of Procainamide can be decreased when combined with Maprotiline.
Isoniazid Isoniazid The metabolism of Maprotiline can be decreased when combined with Isoniazid.
Pyrazinamide Pyrazinamide Pyrazinamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Rifampin Rifampin The metabolism of Maprotiline can be increased when combined with Rifampicin.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of adverse effects can be increased when Valproic acid is combined with Maprotiline.
Tamoxifen Tamoxifen The metabolism of Maprotiline can be decreased when combined with Tamoxifen.
Butabarbital Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Levothyroxine Levothyroxine The risk or severity of adverse effects can be increased when Levothyroxine is combined with Maprotiline.
Liothyronine Liothyronine Liothyronine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Methimazole Methimazole The metabolism of Maprotiline can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide Chlorpropamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Glucagon Injection Glucagon Injection Maprotiline may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide Tolbutamide Maprotiline may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolazamide Tolazamide Tolazamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Maprotiline.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Maprotiline.
Niacin Niacin The metabolism of Maprotiline can be decreased when combined with Niacin.
Baclofen Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Cyproheptadine Cyproheptadine Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorpheniramine.
Brompheniramine Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Meclizine Meclizine Meclizine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ethambutol Ethambutol Ethambutol may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Methyclothiazide Methyclothiazide Maprotiline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dantrolene Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Chlorzoxazone Chlorzoxazone Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.
Methocarbamol Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Maprotiline.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Propranolol.
Pseudoephedrine Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Maprotiline.
Nortriptyline Nortriptyline The metabolism of Maprotiline can be decreased when combined with Nortriptyline.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Phytonadione Phytonadione Maprotiline may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nadolol Nadolol Maprotiline may decrease the excretion rate of Nadolol which could result in a higher serum level.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Maprotiline.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Maprotiline.
Allopurinol Allopurinol Allopurinol may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Maprotiline.
Trimethobenzamide Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Flavoxate Flavoxate Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Fluorouracil.
Colchicine Colchicine Maprotiline may decrease the excretion rate of Colchicine which could result in a higher serum level.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dacarbazine Dacarbazine The metabolism of Maprotiline can be decreased when combined with Dacarbazine.
Acetazolamide Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ketoconazole Ketoconazole The metabolism of Maprotiline can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Thiotepa Injection Thiotepa Injection The therapeutic efficacy of Maprotiline can be decreased when used in combination with Thiotepa.
Isoxsuprine Isoxsuprine The risk or severity of Tachycardia can be increased when Maprotiline is combined with Isoxsuprine.
Vinblastine Vinblastine The metabolism of Maprotiline can be decreased when combined with Vinblastine.
Ethacrynic Acid Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Metoprolol Metoprolol The metabolism of Maprotiline can be decreased when combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Maprotiline.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Maprotiline is combined with Thiothixene.
Aspirin Aspirin Acetylsalicylic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Salsalate Salsalate Salsalate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Alprazolam Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Maprotiline.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Maprotiline.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Maprotiline.
Dicyclomine Dicyclomine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline Propantheline Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim Trimethoprim may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Diltiazem.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Nifedipine.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Maprotiline.
Verapamil Verapamil The metabolism of Maprotiline can be decreased when combined with Verapamil.
Atenolol Atenolol The metabolism of Maprotiline can be decreased when combined with Atenolol.
Pindolol Pindolol Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Pindolol.
Cisplatin Injection Cisplatin Injection Cisplatin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Diflunisal Diflunisal Diflunisal may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Bumetanide Bumetanide Bumetanide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Streptozocin Streptozocin The metabolism of Maprotiline can be increased when combined with Streptozocin.
Etoposide Etoposide The metabolism of Maprotiline can be decreased when combined with Etoposide.
Glipizide Glipizide Maprotiline may decrease the excretion rate of Glipizide which could result in a higher serum level.
Indapamide Indapamide Indapamide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin Amoxicillin Maprotiline may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection Nafcillin Injection The metabolism of Maprotiline can be increased when combined with Nafcillin.
Oxacillin Injection Oxacillin Injection Oxacillin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Pentoxifylline Pentoxifylline The metabolism of Maprotiline can be decreased when combined with Pentoxifylline.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Pentamidine.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Labetalol Labetalol The metabolism of Maprotiline can be decreased when combined with Labetalol.
Auranofin Auranofin Maprotiline may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Leuprolide.
Gemfibrozil Gemfibrozil The metabolism of Maprotiline can be decreased when combined with Gemfibrozil.
Guanabenz Guanabenz The metabolism of Maprotiline can be decreased when combined with Guanabenz.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Pimozide Pimozide The metabolism of Pimozide can be decreased when combined with Maprotiline.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Amiodarone Amiodarone The metabolism of Maprotiline can be decreased when combined with Amiodarone.
Aztreonam Injection Aztreonam Injection Aztreonam may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Buspirone Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Maprotiline.
Lovastatin Lovastatin The metabolism of Maprotiline can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The metabolism of Maprotiline can be decreased when combined with Ciprofloxacin.
Mesalamine Mesalamine Mesalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Fluoxetine Fluoxetine The serum concentration of Maprotiline can be increased when it is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Nimodipine.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The metabolism of Maprotiline can be decreased when combined with Interferon alfa-2b.
Clozapine Clozapine The metabolism of Maprotiline can be decreased when combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Maprotiline is combined with Estazolam.
Idarubicin Idarubicin The metabolism of Idarubicin can be decreased when combined with Maprotiline.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ofloxacin.
Didanosine Didanosine Didanosine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Pentostatin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Clarithromycin.
Etodolac Etodolac Etodolac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Felodipine Felodipine The metabolism of Felodipine can be decreased when combined with Maprotiline.
Fosinopril Fosinopril Fosinopril may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Simvastatin Simvastatin The metabolism of Maprotiline can be decreased when combined with Simvastatin.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Itraconazole.
Lisinopril Lisinopril Lisinopril may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Sotalol Sotalol The metabolism of Sotalol can be decreased when combined with Maprotiline.
Bisoprolol Bisoprolol Bisoprolol may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Zolpidem Zolpidem Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The metabolism of Maprotiline can be decreased when combined with Doxazosin.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Maprotiline.
Omeprazole Omeprazole The metabolism of Maprotiline can be increased when combined with Omeprazole.
Cisapride Cisapride The metabolism of Maprotiline can be decreased when combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Maprotiline is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Maprotiline.
Venlafaxine Venlafaxine The metabolism of Maprotiline can be decreased when combined with Venlafaxine.
Nizatidine Nizatidine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Nizatidine.
Fluvoxamine Fluvoxamine The metabolism of Maprotiline can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Maprotiline is combined with Nefazodone.
Lamotrigine Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Maprotiline.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Maprotiline.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Maprotiline.
Vinorelbine Injection Vinorelbine Injection The metabolism of Maprotiline can be decreased when combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Maprotiline.
Lansoprazole Lansoprazole The metabolism of Maprotiline can be decreased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection Maprotiline may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Nicardipine Nicardipine The metabolism of Maprotiline can be decreased when combined with Nicardipine.
Bupropion Bupropion The risk or severity of seizure can be increased when Maprotiline is combined with Bupropion.
Ticlopidine Ticlopidine The metabolism of Maprotiline can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Saquinavir.
Metformin Metformin Metformin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nisoldipine Nisoldipine Nisoldipine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Lamivudine Lamivudine Lamivudine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Riluzole Riluzole Riluzole may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Acarbose Acarbose Acarbose may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Gemcitabine Injection Gemcitabine Injection Gemcitabine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ritonavir Ritonavir The metabolism of Maprotiline can be decreased when combined with Ritonavir.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Meropenem Injection Meropenem Injection Meropenem may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Clomipramine Clomipramine The metabolism of Maprotiline can be decreased when combined with Clomipramine.
Zafirlukast Zafirlukast The metabolism of Maprotiline can be decreased when combined with Zafirlukast.
Fosfomycin Fosfomycin Fosfomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Mirtazapine Mirtazapine Maprotiline may increase the serotonergic activities of Mirtazapine.
Topiramate Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Maprotiline is combined with Topiramate.
Zileuton Zileuton The metabolism of Maprotiline can be decreased when combined with Zileuton.
Insulin Lispro Injection Insulin Lispro Injection The metabolism of Maprotiline can be increased when combined with Insulin lispro.
Pramipexole Pramipexole Maprotiline may increase the sedative activities of Pramipexole.
Donepezil Donepezil The therapeutic efficacy of Maprotiline can be decreased when used in combination with Donepezil.
Nelfinavir Nelfinavir The metabolism of Maprotiline can be decreased when combined with Nelfinavir.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Azithromycin.
Loratadine Loratadine Maprotiline may increase the anticholinergic activities of Loratadine.
Carvedilol Carvedilol The metabolism of Carvedilol can be decreased when combined with Maprotiline.
Nilutamide Nilutamide Nilutamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Flutamide Flutamide The metabolism of Maprotiline can be decreased when combined with Flutamide.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Maprotiline can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline.
Propafenone Propafenone The metabolism of Maprotiline can be decreased when combined with Propafenone.
Tamsulosin Tamsulosin Tamsulosin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ropinirole Ropinirole Maprotiline may increase the sedative activities of Ropinirole.
Quetiapine Quetiapine The risk or severity of adverse effects can be increased when Maprotiline is combined with Quetiapine.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cetirizine Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Paroxetine Paroxetine The metabolism of Maprotiline can be decreased when combined with Paroxetine.
Tolcapone Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Citalopram Citalopram The risk or severity of adverse effects can be increased when Citalopram is combined with Maprotiline.
Capecitabine Capecitabine Maprotiline may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Efavirenz Efavirenz The metabolism of Maprotiline can be decreased when combined with Efavirenz.
Abacavir Abacavir Maprotiline may decrease the excretion rate of Abacavir which could result in a higher serum level.
Sildenafil Sildenafil The metabolism of Maprotiline can be decreased when combined with Sildenafil.
Celecoxib Celecoxib The metabolism of Maprotiline can be decreased when combined with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Maprotiline can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Balsalazide Balsalazide Balsalazide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nateglinide Nateglinide Nateglinide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Maprotiline.
Levetiracetam Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Rabeprazole Rabeprazole The metabolism of Rabeprazole can be increased when combined with Maprotiline.
Terbinafine Terbinafine The metabolism of Maprotiline can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists